Trial Profile
Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARCHER-1009
- Sponsors Pfizer
- 30 May 2016 Results (correction to previously published (citation #3168334) pooled subset analysis of ARCHER 1009 and A7471028 studies, n = 121) published in the Annals of Oncology.
- 13 Jan 2016 Results of subgroup analysis of pooled data from two studies (ARCHER 1009 and A7471028) published in the Annals of Oncology
- 09 Sep 2015 Results of pooled analysis of A7471028 and ARCHER 1009 study presented at the 16th World Conference on Lung Cancer.